Radiopharm Theranostics Q2 2026: Cash Runway Drops Below One Quarter, but Clinical Wins and Post-Quarter Raises Offer a Bridge
RADX is trading near its 52-week low of $2.73 (7.5% above the low).
Summary
Radiopharm Theranostics' Q2 2026 report reveals a cash balance of A$4.1 million and only 0.28 quarters of runway, but post-quarter capital raises exceeding A$20 million and positive clinical data for RAD 101 and RAD 204 deliver a critical lifeline.
Key Events · Earnings and Guidance · RADX
-
Cash Runway Below One Quarter
Cash and equivalents fell to A$4.1 million at June 30, 2026, from A$19.2 million in the prior quarter. Net operating cash outflow was A$14.97 million, yielding only 0.28 quarters of funding available.
-
Post-Quarter Capital Raises
After the quarter end, the company received a A$5.9 million R&D tax incentive, completed a A$12.5 million institutional offer, and launched a A$6 million Share Purchase Plan (A$3 million already subscribed), providing over A$20 million in new capital.
-
RAD 101 Phase 2b Meets Primary Endpoint
93% of evaluable patients achieved concordance with MRI imaging. An interim analysis of 14 patients showed 86% sensitivity. A Phase 3 registrational trial is planned for Q4 2026.
-
RAD 204 Durable Partial Response
The first patient in the third cohort (90mCi) of the Phase 1 trial achieved a RECIST-confirmed partial response with tumor shrinkage up to -43%, remaining progression-free for over 7 months.
Analysis · RADX · Life Sciences
A critical cash position of A$4.1 million at June 30, 2026, and net operating outflows of A$14.97 million leave Radiopharm Theranostics with just 0.28 quarters of funding—a clear going-concern red flag. Yet the company has already moved to shore up its finances: after the quarter closed, it secured a A$5.9 million R&D tax refund, completed a A$12.5 million institutional placement, and launched a A$6 million share purchase plan, of which A$3 million has already been subscribed. These post-quarter events, together with encouraging clinical updates—including a 93% primary endpoint achievement in the RAD 101 Phase 2b trial and a durable partial response in the RAD 204 Phase 1 trial—provide a near-term funding bridge and validate the pipeline. The filing is highly material because it simultaneously lays bare severe cash constraints and the immediate steps taken to mitigate them, alongside clinical progress that could support future financing or partnerships.
At the time of this filing, RADX was trading at $2.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.6M. The 52-week trading range was $2.73 to $16.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.